Home › Funds › LOS ANGELES CAPITAL MANAGEMENT LLC › ALNY

LOS ANGELES CAPITAL MANAGEMENT LLC position in ALNY

ALNYLAM PHARMACEUTICALS INC · Health Care

LOS ANGELES CAPITAL MANAGEMENT LLC reported holding 729,635 shares of ALNY (ALNYLAM PHARMACEUTICALS INC) in its Q2 2026 13F filing — a position valued at US$219.6M, representing 0.81% of its reported portfolio and ranking #18 among its reported holdings. LOS ANGELES CAPITAL MANAGEMENT LLC has disclosed ALNY holdings in 11 of the last 11 reported quarters, going back to Q4 2023.

Latest position (Q2 2026)729.63K sh
Reported value held$219.64M
Portfolio Weight0.81%
First reportedQ4 2023
Last changeAdd
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How LOS ANGELES CAPITAL MANAGEMENT LLC's ALNY position evolved

LOS ANGELES CAPITAL MANAGEMENT LLC first disclosed a stake in ALNY in Q4 2023 at 17,028 shares (US$3.3M). The position peaked in Q2 2026 at 729,635 shares, worth US$219.6M. Across 11 filings, LOS ANGELES CAPITAL MANAGEMENT LLC increased the stake 4 time(s), trimmed it 6 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 729,635 shares valued at US$219.6M — an increase of 641,357 shares quarter over quarter.. Notable position changes include a 11433% increase in Q3 2024 (shares fell 14% over the following quarter), a 136% increase in Q3 2025 (shares fell 13% over the following quarter), a 727% increase in Q2 2026 (shares fell 19% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q4 2023 17.03K $3.26M New
Q1 2024 2.96K $442.22K Reduce
Q2 2024 1.19K $288.68K Reduce
Q3 2024 137.02K $37.68M Add
Q4 2024 94.82K $22.31M Reduce
Q1 2025 80.86K $21.83M Reduce
Q2 2025 67.40K $21.98M Reduce
Q3 2025 159.39K $72.68M Add
Q4 2025 240.05K $107.92M Add
Q1 2026 88.28K $29.21M Reduce
Q2 2026 729.63K $219.64M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About ALNY and 13F data

ALNY (ALNYLAM PHARMACEUTICALS INC) is a Health Care company. 35 other funds we track also report a position in ALNY — the largest reported positions include T. Rowe Price Investment Management, Inc. (US$1.70B), Baillie Gifford & Co (US$734.5M), Orbis Allan Gray Ltd (US$598.3M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding ALNY

All ALNY fund holders →

FAQ

How long has LOS ANGELES CAPITAL MANAGEMENT LLC held ALNY?

LOS ANGELES CAPITAL MANAGEMENT LLC has disclosed ALNY holdings in 11 of the last 11 reported quarters, going back to Q4 2023.

What is LOS ANGELES CAPITAL MANAGEMENT LLC's current position in ALNY?

As of Q2 2026, LOS ANGELES CAPITAL MANAGEMENT LLC holds 729.63K shares of ALNY (ALNYLAM PHARMACEUTICALS INC), valued at $219.64M, representing 0.81% of its reported portfolio and ranking #18.

Has LOS ANGELES CAPITAL MANAGEMENT LLC been buying or selling ALNY?

In the latest 13F filing (Q2 2026), LOS ANGELES CAPITAL MANAGEMENT LLC increased its position in ALNY. The position peaked in Q2 2026 at 729.63K shares.

Which other funds hold ALNY?

Other major institutional holders of ALNY include T. Rowe Price Investment Management, Inc., Baillie Gifford & Co, Orbis Allan Gray Ltd, among 35 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.